CRISPR Therapeutics director may sell 13,679 shares

A CRISPR Therapeutics director filed a Rule 144 notice to potentially sell 13,679 common shares tied to a stock option exercise.

Rhea-AI Filing Summary

CRISPR Therapeutics AG (CRSP) is the issuer for which director Ali Behbahani has filed a notice of proposed sale of securities under Rule 144. The filing covers up to 13,679 shares of Common Stock, with an indicated aggregate market value of $780,935.48, in connection with a stock option exercise expected on September 17, 2026, with any sale to be effected for cash through Morgan Stanley Smith Barney LLC on NASDAQ.

Key Figures

Shares covered by Rule 144 notice: 13,679 shares Aggregate market value of securities: $780,935.48 Transaction date: September 17, 2026 +2 more

5 metrics

Shares covered by Rule 144 notice 13,679 shares Common Stock potentially to be sold under Rule 144

Aggregate market value of securities $780,935.48 Value associated with the 13,679 common shares covered

Transaction date September 17, 2026 Date tied to stock option exercise and potential sale

Security type Common Stock Class of CRISPR Therapeutics AG securities in the notice

Broker Morgan Stanley Smith Barney LLC Broker listed for executing the potential sale

Key Terms

Rule 144, stock option exercise, aggregate market value, securities to be sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 09/17/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 13679 | 780935.48"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold financial

"144: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for CRSP?

The Form 144 indicates that director Ali Behbahani may sell up to 13,679 shares of CRISPR Therapeutics AG common stock under Rule 144. It is a notice of a potential resale by an insider, not an issuance of new shares by the company.

How many CRSP shares are covered by this Rule 144 notice?

The notice covers up to 13,679 shares of Common Stock. This amount is tied to a stock option exercise, with any resulting sale to be made for cash through a broker on NASDAQ.

What is the approximate value of the CRSP shares in this Form 144?

The filing lists an aggregate market value of $780,935.48 for the 13,679 shares of CRISPR Therapeutics AG common stock that may be sold under this Rule 144 notice.

Who is selling CRSP shares under this Form 144 and in what capacity?

The potential sale is for the account of Ali Behbahani, identified in the filing as a Director of CRISPR Therapeutics AG. The Form 144 provides required disclosure for a contemplated resale by this insider under Rule 144.

How will the potential CRSP share sale be executed?

The contemplated transaction involves a stock option exercise with any resulting sale for cash through Morgan Stanley Smith Barney LLC Executive Financial Services, with the securities listed for trading on NASDAQ.

When is the CRSP Rule 144 transaction associated with this notice dated?

The Form 144 references September 17, 2026 as the date associated with both the stock option exercise and the securities to be sold section, indicating the timing tied to the contemplated transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:09 PM Accepted by SEC EDGAR 09/17/2026 - 04:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001613867
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CRISPR THERAPEUTICS AG
SEC File Number	001-37923
Address of Issuer	Baarerstrasse 14 Zug SWITZERLAND 6300
Phone	41 (0)41 561 32 77
Name of Person for Whose Account the Securities are To Be Sold	ALI BEHBAHANI
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	13679	780935.48	96692653	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2026	Stock Option Exercise	Issuer			13679	09/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ali Behbahani
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)